Millennium Management Discloses Significant Stake in Indivior Pharma
| Field | Detail |
|---|---|
| Company | Schedule 13g - Indivior Pharmaceuticals, Inc. (0001625297) (Subject) |
| Filed Date | Mar 23, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, schedule-13g, passive-investment
TL;DR
**Millennium Management just revealed a big stake in Indivior Pharma, signaling institutional confidence.**
AI Summary
Millennium Management LLC, a major investment firm, filed a Schedule 13G on March 23, 2026, indicating its beneficial ownership in Indivior Pharmaceuticals, Inc. This filing signals that Millennium Management LLC holds a significant stake in Indivior, which could be seen as a vote of confidence from a large institutional investor. For current or prospective Indivior shareholders, this matters because large institutional ownership can sometimes provide stability and attract further investment, potentially influencing the stock's performance.
Why It Matters
This filing reveals a major institutional investor's position, which can influence market perception and potentially the stock price of Indivior Pharmaceuticals, Inc.
Risk Assessment
Risk Level: low — A Schedule 13G filing generally indicates passive ownership and is not inherently high-risk, but rather a disclosure of a significant stake.
Analyst Insight
An investor might research Millennium Management LLC's investment thesis or other holdings to understand the potential rationale behind this significant stake in Indivior Pharmaceuticals, Inc.
Key Players & Entities
- Millennium Management LLC (company) — the entity filing the Schedule 13G
- Indivior Pharmaceuticals, Inc. (company) — the subject company in which ownership is being reported
- March 23, 2026 (date) — the filing date of the Schedule 13G
FAQ
What type of filing is this and who filed it?
This is a SCHEDULE 13G filing, which was filed by MILLENNIUM MANAGEMENT LLC regarding its beneficial ownership in Indivior Pharmaceuticals, Inc.
When was this filing submitted and accepted?
The filing was submitted and accepted on 2026-03-23.
What is the CIK for Indivior Pharmaceuticals, Inc.?
The CIK for Indivior Pharmaceuticals, Inc. is 0001625297.
Filing Stats: 157 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2026-03-23 17:19:04
Key Financial Figures
- $0.001 — ersigned of the Common Stock, par value $0.001 per share, of Indivior Pharmaceuticals,
Filing Documents
- primary_doc.html (SCHEDULE 13G)
- primary_doc.xml (SCHEDULE 13G) — 9KB
- tm269609d1_ex-1.htm (EX-99.1) — 5KB
- 0001104659-26-033404.txt ( ) — 16KB
From the Filing
EX-99.1 2 tm269609d1_ex-1.htm EXHIBIT 1 EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.001 per share, of Indivior Pharmaceuticals, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Dated: March 20, 2026 MILLENNIUM MANAGEMENT LLC By: /s/ Gil Raviv Name: Gil Raviv Title: Global General Counsel MILLENNIUM GROUP MANAGEMENT LLC By: /s/ Gil Raviv Name: Gil Raviv Title: Global General Counsel /s/ Israel A. Englander Israel A. Englander